ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
11 hedge funds and large institutions have $901K invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
2.83% less ownership
Funds ownership: 10.1% → 7.26% (-2.8%)
15% less funds holding
Funds holding: 13 → 11 (-2)
36% less capital invested
Capital invested by funds: $1.4M → $901K (-$504K)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$76.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$295K |
| 2 |
Morgan Stanley
New York
|
-$225K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$140K |
| 4 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$50.4K |
| 5 |
RIA
Realta Investment Advisors
Wilmington,
Delaware
|
-$7.28K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Focus Partners Wealth
Boston,
Massachusetts
| $558K | -$50.4K | -3,418 | -8% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $165K | -$140K | -9,535 | -46% |
|
|
3
UBS Group
Zurich,
Switzerland
| $79.9K | +$76.7K | +5,207 | +3,773% |
|
|
4
Morgan Stanley
New York
| $75.4K | -$225K | -15,272 | -75% |
|
|
BBPWM
5
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $10.8K | – | – | – |
|
|
NFSG
6
Newbridge Financial Services Group
Boca Raton,
Florida
| $4.49K | – | – | – |
|
7
Osaic Holdings
Scottsdale,
Arizona
| $3.15K | – | – | – |
|
|
SWA
8
SOA Wealth Advisors
New York
| $2.24K | – | – | – |
|
|
NA
9
NewEdge Advisors
New Orleans,
Louisiana
| $1.5K | – | – | – |
|
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$295K | -20,045 | -100% |
|
|
CPA
11
Clear Point Advisors
Melville,
New York
| $403 | – | – | – |
|
12
Wells Fargo
San Francisco,
California
| $7 | – | – | – |
|
|
RIA
13
Realta Investment Advisors
Wilmington,
Delaware
| – | -$7.28K | -539 | Closed |
|
|
CA
14
CoreCap Advisors
Southfield,
Michigan
| – | -$1.45K | -108 | Closed |
|
CNCR Hedge Fund Activity: Q3 2024 in Review
11 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q3 2024, worth a combined $901K — down 36% from $1.4M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CNCR and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $76.7K. The largest seller was Royal Bank of Canada, cutting an estimated $295K.
- 11 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q3 2024, down from 13 in Q2 2024.
- Funds reported $901K of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q3 2024, down 36% quarter-over-quarter.
- 0 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q3 2024 and 2 closed out, a net change of -2 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q3 2024 was UBS Group, an estimated $76.7K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q3 2024 was Royal Bank of Canada, an estimated $295K sold.
Based on aggregated 13F filings for Q3 2024.